This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Varian (VAR) ProBeam Proton Therapy System Now in Thailand
by Zacks Equity Research
Leading manufacturer of medical devices and software, Varian Medical Systems, Inc. (VAR) has sealed another international deal for its Proton therapy platform.
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment
by Zacks Equity Research
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment
LabCorp Offers Sera's PreTRM to Assess Preterm Birth Risk
by Zacks Equity Research
Leading diagnostics testing company LabCorp (LH) recently announced the availability of Sera Prognostics, Inc.'s PreTRM test at its laboratories in the U.S.
Integra LifeSciences to Offer aap's LOQTEQ System in the US
by Zacks Equity Research
Global medical technology major, Integra LifeSciences Holdings Corporation (IART) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker.
Quality Systems Professional Service a Drag, Competition Rife
by Zacks Equity Research
On May 23, we issued an updated research report on Irvine, CA-based Quality Systems Inc. (QSII), a leading developer and marketer of healthcare information systems.
Envision (EVHC) Acquires Gwinnett Emergency Specialists
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) announced the acquisition of Gwinnett Emergency Specialists, P.C.
Halyard Health (HYH) Expands CORGRIP System Product Line
by Zacks Equity Research
Halyard Health (HYH), a leading medical technology company, recently announced the expansion of its CORGRIP Nasogastric/Nasointestinal Tube Retention System product line.
Hologic (HOLX) Poised on Balanced Growth Amid Currency Woes
by Zacks Equity Research
On May 23, we issued an updated research report on Bedford, MA-based Hologic Inc. (HOLX).
Avoid Market Volatility with 5 Low-Beta Stocks
by Zacks Equity Research
In this article, we present a strategy which proves that low risky securities can also reap rewards if some specific parameters are considered.
IDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects
by Zacks Equity Research
On May 22, IDEXX Laboratories, Inc. (IDXX), a leading manufacturer of products and services primarily for the companion animal veterinary, was raised by a notch to a Zacks Rank #2 (Buy).